{"entity":{"id":"nct06105619","kind":"trial","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","aka":[],"tldr":"A phase 2/3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company, active.","summary":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). is a phase 2/3 interventional study registered as NCT06105619 by Beijing Pearl Biotechnology Limited Liability Company, with 84 participants enrolled, started 2018-10-08. Conditions listed: Glioblastoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06105619","url":"https://clinicaltrials.gov/study/NCT06105619"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06105619","phase":"2/3","setting":"A Randomized, Controlled, Open, Multicenter, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of Vebreltinib Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","enrolled":84,"outcomes":[]},"route":"/trials/nct06105619/","neighbours":{"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}]}}